USOO8828703B2 (12) UnitedO States Patent (10) Patent No.: US 8,828,703 B2 Ladner (45) Date of Patent: Sep. 9, 2014 (54) PROTEASE INHIBITION 6,423,498 B1 7/2002 Markland et al. 6,534,276 B1 3/2003 Wun et al. (75) Inventor: Robert C. Ladner, Ijamsville, MD (US) 6,583,1086,548,262 B1B2 4/20036/2003 TamburiniGentz et al. et al. (73) Assignee: Dyax Corp., Burlington, MA (US) 6,783,9606,689,582 B2B1 2/20048, 2004 E"Davies et al. 6,806,360 B2 10/2004 Wun et al. (*) Notice: Subject to any disclaimer, the term of this 6,914, 135 B2 7/2005 Sheppard et al. patent is extended or adjusted under 35 23. R: $39. E. 1 U.S.C. 154(b) by 1314 days. 2002/01W 11460 I A1 8/2002 Hollowaya ca. 2003.0114372 A1 6/2003 White et al. (21) Appl. No.: 11/646,148 2003/01296.59 A1 7, 2003 Whelihan et al. 2003/0175919 A1 9/2003 Ley et al. (22) Filed: Dec. 27, 2006 2004/0152633 A1 8/2004 Jorgensen et al. 2004/0171794 A1 9, 2004 Ladner et al. 65 Prior Publication Dat 2005, 0004021 A1 1/2005 Sprecher et al. (65) O DO 2005, 0164945 A1 7, 2005 Nixon et al. US 2008/O255O25A1 Oct. 16, 2008 2005/O180977 A1 8, 2005 Nixon et al. 2006/0264.603 A1 11/2006 Markland et al. O O 2007/002O252 A1 1/2007 Ladner et al. Related U.S. Application Data 2008/O1394.73 A1 6/2008 Ladner et al. 2009,0264350 A1 10, 2009 Blair et al. (60) gyal application No. 60/754,903, filed on Dec. 2010/0286061 A1 1 1/2010 Devy et al. FOREIGN PATENT DOCUMENTS (51) Int. Cl. CI2N 9/48 (2006.01) EP O 274 826 T 1988 CI2N IS/00 (2006.01) EP O 318 451 5, 1989 CI2P2/06 (2006.01) W8 wo3:56, 38; CI2P 2L/04 (2006.01) WO WOO1? 68.707 9, 2001 (52) U.S. Cl. WO WO 2005/021557 3, 2005 USPC .......... 435/212:435/69.1; 435/71. 1; 435/.440 OTHER PUBLICATIONS (58) Field of Classification Search USPC . 435/212, 69.1, 71.1, 440 Branden et al. Introduction to Protein Structure, Garland Publishing See application file for complete search history. Inc., New York, p. 247, 1991.* Sheffield. Modification of clearance of therapeutic and potentially (56) References Cited therapeutic proteins. Curr Drug Targets Cardiovasc Haematol U.S. PATENT DOCUMENTS Disord. Jun. 2001;1(1):1-22.* Wriggers et al. Control of protein functional dynamics by peptide 4,966,852 A 10, 1990 Wun et al. linkers Biopolymers. 2005:80(6):736-46.* 5,106,833. A 4, 1992 Broze, Jr. et al. International Search Report of International Application No. PCT/ 5,212,091 A 5, 1993 Diaz-Collier et al. US06/49322 mailed Dec. 7, 2007. 5,223,409 A 6, 1993 Ladner et al. Fries et al., Inter-alpha-inhibitor, hyaluronan and inflammation, Acta 5,312,736 A 5/1994 Rasmussen et al. Biochimica Polonica, 2003, vol. 50, No. 3, pp. 735-742. 5,378,614 A 1/1995 Petersen et al. Magkl 5,455,338 A 10/1995 Sprecher et al. agklara1-rap eta al., Characterization of the enzymaticM activity of human 5,466,783 A 11/1995 Wun et al. kallikrein 6:Autoactivation, Substrate specificity, and regulation by 5,563,123 A 10, 1996 Innis et al. inhibitors, Biochem. Biophys. Res. Commun., Aug. 2003, 5,589.359 A 12/1996 Innis et al. 8:307(4):948-55, abstract only. 5,618,696 A 4/1997 Norris et al. Scarff et al., Targeted Disruption of SP13/Serpinb6 DoesNot Result 5,629, 176 A 5/1997 Bjorn et al. in Developmental or Growth Defects, Leukocyte Dysfunction, or s A 3. 1992 di t al. Susceptibility to Stroke, Molecular and Cellular Biology, May 2004, ww- ey et al. pp. 4075-4082. s: A 3. R et al 1 Taggart et al., Inactivation of Human beta-Defensins 2 and 3 by 5,780,265- w A 7, 1998 Denniselley etet al.al. Eatolytic Cathepsins 1. TheJournal ofImmunology, 2003, 170:931* V - 5,786.328 A 7, 1998 Dennis et al. 5,795,954. A 8, 1998 Lazarus et al. 5,834,244. A 1 1/1998 Dennis et al. (Continued) 5,863,893 A 1/1999 Dennis et al. 5,880,256 A 3/1999 Dennis et al. Primary Examiner —Yong Pak 5,914,316 A 6, 1999 Brown et al. (74) Attorney, Agent, or Firm — Wolf, Greenfield & Sacks, 6,008,196 A 12/1999 Curran et al. P.C. 6,057,287 A 5, 2000 Markland et al. 6,063,764 A 5/2000 Creasey et al. 6,071,723 A 6, 2000 Markland et al. (57) ABSTRACT 6,103,500 A 8, 2000 Innis et al. Proteins including engineered sequences which inhibit pro 6,174,7216,171,587 B1 1/2001 WunInnis etet al. teases are disclosed, including proteins having two or more 6,180,607 B1 1/2001 Davies et al. engineered KunitZ domains, and uses of Such proteins. 6,242,414 B1 6/2001 Johnson et al. 6,333,402 B1 12/2001 Markland et al. 7 Claims, No Drawings US 8,828.703 B2 Page 2 (56) References Cited Mine et al., “Strutural Mechanism for Heparin-Binding of the Third Kunitz Domain of Human Tissue Factor Pathway Inhibitor.” Bio OTHER PUBLICATIONS chemistry, 41:78-85 (2002). Novotny et al., “Purification and Characterization of the Lipoprotein Borregaard and Cowland, “Granules of the Human Neutrophilic associated Coagulation Inhibitor from Human Plasma.” The Journal Polymorphonuclear Leukocyte.” Blood, 89(10):3503-3521 (1997). of Biological Chemistry, 264(31): 18832-18837 (1989). Burrage et al., “Matrix Metalloproteinases: Role in Arthritis.” (2006). Petersen et al., “Inhibitory properties of separate recombinant Frontiers in Bioscience, 11:529-543. Kunitz-type-protease-inhibitor domains from tissue-factor-pathway Cassim et al., “Kallikrein cascade and cytokines in inflamed joints.” inhibitor.” Eu. J. Biochem. 235:310-316 (1996). Pharmacology & Therapeutics, 94:1-34 (2002). Pintigny and Dachary-Prigent, "Aprotinin can inhibit the proteolytic Churg and Wright, “Proteases and emphysema.” Curr. Opin. Pulm. activity of thrombin: A fluorescence and an enzymatic study.” Eur: J. Biochem. 207:89-95 (1992). Med., 11:153-159 (2005). Piro et al., “Role for the Kunitz-3 Domain of Tissue Factor Pathway Colman, Robert W., “Plasma and tissue kallikrein in arthritis and Inhibitor-O in Cell Surface Binding.” Circulation, 110:3567-3572 inflammatory bowel disease.” Immunopharmacology, 43:103-108 (2004). (1999). Rahman et al., “Identification and functional importance of plasma Cunningham et al., “Structural and functional characterization of kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, tissue factor pathway inhibitor following degradation by matrix and osteoarthritis.” Annals of the Rheumatic Diseases, 54:345-350 metalloproteinase-8.” Biochem. J., 367:451-458 (2002). (1995). Dela Cadena et al., “Inhibition of plasma kallikrein prevents Sprecher et al., “Molecular Cloning. Expression, and Partial Charac peptidoglycan-induced arthritis in the Lewis rat.” FASEB.J., 9:446 terization of a Second Human Tissue-Factor-Pathway Inhibitor.” 452 (1995). Proceedings of the National Academy of Sciences of the United States Devani et al., “Kallikrein-kinin system in inflammatory bowel dis of America, 91 (8):3353-3357 (1994). eases: Intestinal involvement and correlation with the degree of tissue Stadnicki et al., “Activation of Plasma Contact and Coagulation inflammation.” Digestive and Liver Disease, 37:665-673 (2005). Systems and Neutrophils in the Active Phase of Ulcerative Colitis.” Eigenbrotet al., “Structural effects induced by removal of a disulfide Digestive Diseases and Sciences, 42(11):2356-2366 (1997). bridge: the X-ray structure of the C30A/C51A mutant of basic pan Taby et al., “Inhibition of Activated Protein C by Aprotinin and the creatic trypsin inhibitor at 1.6 A.” Protein Engineering,3(7):591-598 Use of the Insolubilized Inhibitor for its Purification.” Thrombosis (1990). Research, 59:27-35 (1990). Girard et al., “Functional significance of the Kunitz-type inhibitory Tremblay et al., “Anti-inflammatory activity of neutrophil elastase domains of lipoprotein-associated coagulation inhibitor.” Nature, inhibitors.” Current Opinion in Investigational Drugs, 4(5):556-565 338:518-520 (1989). (2003). Gulberg et al., “BioSynthesis, processing and sorting of neutrophil Volpe-Junior et al., “Augmented plasma and tissue kallikrein like proteins: insight into neutrophil granule development. Eur: Journal activity in Synovial fluid of patients with inflammatory articular of Haematology, 58:137-153 (1997). diseases.” Inflamm. Res., 45:198-202 (1996). Hagihara et al., “Screening for Stable Mutants with Amino Acid Pairs Wun et al., “Cloning and Characterization of a cDNA Coding for the Substituted for the Disulfide Bond between Residues 14 and 38 of Lipoprotein-associated Coagulation Inhibitor Shows that it Consists Bovine Pancreatic Trypsin Inhibitor (BPTI).” The Journal of Biologi of Three Tandem Kunitz-type Inhibitory Domains.” The Journal of cal Chemistry, 277(52):51043-5 1048 (2002). Biological Chemistry, 263(13):6001-6004 (1988). Herter et al., “Hepatocyte growth factor is a preferred in vitro Sub Delgado, C., “The Uses and Properties of PEG-Linked Proteins”. strate for human hepsin, a membrane-anchored serine protease impli Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4):249 cated in prostate and ovarian cancers.” Biochem. J. 390:125-136 304 (1992). (2005). Dhalluin, C., "Structural, Kinetic, and Thermodynamic Analysis of Huang et al., “Kinetics of Factor Xa. Inhibition by Tissue Factor the Binding of the 40 kDa PEG-Interferon-C2a and Its Individual Pathway Inhibitor.” The Journal of Biological Chemistry, Positional Isomers to the Extracellular Domain of the Receptor 268(36): 26950-26955 (1993).